picankibart vs TL-003

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: IL-23 p19 · full Ulcerative Colitis pipeline

picankibart

Marketed by Innovent Biologics

Phase 2 in Ulcerative Colitismonoclonal antibody (anti-IL-23p19)
Partial signal

NCT05377580 · Phase 2 · completed

This randomized, quadruple-blind, placebo-controlled Phase 2 trial enrolled 150 patients with moderately to severely active ulcerative colitis and tested several doses of picankibart against placebo. The primary endpoint was clinical remission at Week 12. The sponsor reported remission in 20.0% of patients on 200 mg and 14.0% on 600 mg versus 2.0% on placebo (p<0.05), so the primary endpoint was met; no power calculation or planned enrolment was found in the sources checked.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Evaluate the effectiveness of IBI112 in inducing clinical remission in patients with moderately to severely active ulcerative colitis (UC) (week 12): Week 12 clinical remission (primary endpoint): picankibart 200 mg 20.0% and 600 mg 14.0% vs placebo 2.0% (p<0.05). (met)

Result source: NCT05377580

TL-003

Developed by Bionyra Pharma under a licence from TrueLab Biopharmaceutical

Phase 1 in Ulcerative Colitisbispecific antibody (anti-TL1A/IL-23, extended half-life)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: April 2027 · NCT07526519 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointpicankibartTL-003
Clinical remission (induction)—Not reported—Not reported
Clinical remission (maintenance)—Not reported—Not reported
Clinical response (induction)—Not reported—Not reported
Endoscopic improvement (induction)—Not reported—Not reported
Corticosteroid-free remission (maintenance)—Not reported—Not reported

Clinical remission (induction)

picankibart
—Not reported
TL-003
—Not reported

Clinical remission (maintenance)

picankibart
—Not reported
TL-003
—Not reported

Clinical response (induction)

picankibart
—Not reported
TL-003
—Not reported

Endoscopic improvement (induction)

picankibart
—Not reported
TL-003
—Not reported

Corticosteroid-free remission (maintenance)

picankibart
—Not reported
TL-003
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

TL-003: no structured comparison results are available for Ulcerative Colitis.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

picankibart
Week 12 clinical remission (primary endpoint): picankibart 200 mg 20.0% and 600 mg 14.0% vs placebo 2.0% (p<0.05). NCT05377580 · Phase 2 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: picankibart's landscape · TL-003's landscape